Lisa Klingelhoefer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lisa Klingelhoefer has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Heinz Reichmann
Department of Neurology, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany
5 shared publications- Kallol Ray Chaudhuri
King’s College Hospital
4 shared publications Anna Sauerbier
Department of Basic and Clinical Neurosciences Institute of Psychiatry, Psychology and Neuroscience King’s College London London UK
3 shared publicationsH. Reichmann
Department of Neurology, Technical University Dresden, Dresden
3 shared publicationsK. Ray Chaudhuri
Department of Neurology, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany
3 shared publicationsRobert Untucht
Department of Neurology, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany
3 shared publications
Latest Publications
- Open Access
- 26 June 2024
- Published by Association for Computing Machinery (ACM)
- p. 554-561
Can bite detection algorithms substitute manual video annotations in elderly people with and without Parkinson’s disease? An experimental study
Parkinson’s disease, as a neurodegenerative disorder that affects movement, can significantly affect patients’ nutrition, potentially leading to malnutrition and weight loss. Therefore, monitoring the eating behavior of Parkinsons’ patients in real-time could better inform when interventions are needed to maintain or increase energy intake and improve the overall quality of life of patients, while reducing the disease severity. Traditional eating behavior analysis methods rely on self-reported measures, whose reliability is limited due to miss-reporting. This work aims to assess the ability of an automated algorithm to accurately idenitfy eating characteristics based on video inputs. Experimental results show the proposed deep learning-based algorithm achieves a near-perfect agreement (correlation coefficient 0.95) with manual annotation of bite instances, thus paving the way for the creation of automated eating behavior monitoring systems with the potential to be integrated with current clinical practice for improved Parkinson’s disease assessment and handling.
- 26 June 2024
- Published by Association for Computing Machinery (ACM)
- p. 554-561
Open AccessCan bite detection algorithms substitute manual video annotations in elderly people with and without Parkinson’s disease? An experimental study
Parkinson’s disease, as a neurodegenerative disorder that affects movement, can significantly affect patients’ nutrition, potentially leading to malnutrition and weight loss. Therefore, monitoring the eating behavior of Parkinsons’ patients in real-time could better inform when interventions are needed to maintain or increase energy intake and improve the overall quality of life of patients, while reducing the disease severity. Traditional eating behavior analysis methods rely on self-reported measures, whose reliability is limited due to miss-reporting. This work aims to assess the ability of an automated algorithm to accurately idenitfy eating characteristics based on video inputs. Experimental results show the proposed deep learning-based algorithm achieves a near-perfect agreement (correlation coefficient 0.95) with manual annotation of bite instances, thus paving the way for the creation of automated eating behavior monitoring systems with the potential to be integrated with current clinical practice for improved Parkinson’s disease assessment and handling.
- Open Access
- 28 March 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1149604
The Gut Dysmotility Questionnaire for Parkinson's disease: Insights into development and pretest studies
Objective: A total of 48% of patients with Parkinson's disease (PD) present symptoms of gastrointestinal dysfunction, particularly constipation. Furthermore, gastrointestinal tract (GIT)-related non-motor symptoms (NMSs) appear at all stages of PD, can be prodromal by many years and have a relevant impact on the quality of life. There is a lack of GIT-focused validated tools specific to PD to assess their occurrence, progress, and response to treatment. The aim of this study was to develop and evaluate a novel, disease- and symptom-specific, self-completed questionnaire, titled Gut Dysmotility Questionnaire (GDQ), for screening and monitoring gastrointestinal dysmotility of the lower GIT in patients with PD.Methods: In phase 1, a systematic literature review and multidisciplinary expert discussions were conducted. In phase 2, cognitive pretest studies comprising standard pretests, interviews, and evaluation questionnaires were performed in patients with PD (n = 21), age- and sex-matched healthy controls (HC) (n = 30), and neurologists (n = 11). Incorporating these results, a second round of cognitive pretests was performed investigating further patients with PD (n = 10), age- and sex-matched HC (n = 10), and neurologists (n = 5). The questionnaire was adapted resulting in the final GDQ, which underwent cross-cultural adaptation to the English language.Results: We report significantly higher GDQ total scores and higher scores in five out of eight domains indicating a higher prevalence of gastrointestinal dysmotility in patients with PD than in HC (p < 0.05). Cognitive pretesting improved the preliminary GDQ so that the final GDQ was rated as relevant (100/100%), comprehensive (100/90%), easy to understand concerning questions and answer options (100/90%), and of appropriate length (80/100%) by neurologists and patients with PD, respectively. The GDQ demonstrated excellent internal consistency (Cronbach‘s alpha value of 0.94). Evidence for good construct validity is given by moderate to high correlations of the GDQ total score and its domains by intercorrelations (rs = 0.67–0.91; p < 0.001) and with validated general NMS measures as well as with specific items that assess gastrointestinal symptoms.Interpretation: The GDQ is a novel, easy, and quick 18-item self-assessment questionnaire to screen for and monitor gastrointestinal dysmotility with a focus on constipation in patients with PD. It has shown high acceptance and efficacy as well as good construct validity in cognitive pretests.
- 28 March 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1149604
Open AccessThe Gut Dysmotility Questionnaire for Parkinson's disease: Insights into development and pretest studies
Objective: A total of 48% of patients with Parkinson's disease (PD) present symptoms of gastrointestinal dysfunction, particularly constipation. Furthermore, gastrointestinal tract (GIT)-related non-motor symptoms (NMSs) appear at all stages of PD, can be prodromal by many years and have a relevant impact on the quality of life. There is a lack of GIT-focused validated tools specific to PD to assess their occurrence, progress, and response to treatment. The aim of this study was to develop and evaluate a novel, disease- and symptom-specific, self-completed questionnaire, titled Gut Dysmotility Questionnaire (GDQ), for screening and monitoring gastrointestinal dysmotility of the lower GIT in patients with PD.Methods: In phase 1, a systematic literature review and multidisciplinary expert discussions were conducted. In phase 2, cognitive pretest studies comprising standard pretests, interviews, and evaluation questionnaires were performed in patients with PD (n = 21), age- and sex-matched healthy controls (HC) (n = 30), and neurologists (n = 11). Incorporating these results, a second round of cognitive pretests was performed investigating further patients with PD (n = 10), age- and sex-matched HC (n = 10), and neurologists (n = 5). The questionnaire was adapted resulting in the final GDQ, which underwent cross-cultural adaptation to the English language.Results: We report significantly higher GDQ total scores and higher scores in five out of eight domains indicating a higher prevalence of gastrointestinal dysmotility in patients with PD than in HC (p < 0.05). Cognitive pretesting improved the preliminary GDQ so that the final GDQ was rated as relevant (100/100%), comprehensive (100/90%), easy to understand concerning questions and answer options (100/90%), and of appropriate length (80/100%) by neurologists and patients with PD, respectively. The GDQ demonstrated excellent internal consistency (Cronbach‘s alpha value of 0.94). Evidence for good construct validity is given by moderate to high correlations of the GDQ total score and its domains by intercorrelations (rs = 0.67–0.91; p < 0.001) and with validated general NMS measures as well as with specific items that assess gastrointestinal symptoms.Interpretation: The GDQ is a novel, easy, and quick 18-item self-assessment questionnaire to screen for and monitor gastrointestinal dysmotility with a focus on constipation in patients with PD. It has shown high acceptance and efficacy as well as good construct validity in cognitive pretests.
- Top Cited PapersOpen Access
- 7 March 2023
- Published by Wiley in European Journal of Neurology
- Vol. 30 (5) , 1465-1480
Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease
Levodopa is the gold standard for the symptomatic treatment of Parkinson's disease (PD). There are well documented motor and non‐motor fluctuations, however, that occur almost inevitably once levodopa is started after a variable period in people with PD. Whilst brain neurodegenerative processes play a part in the pathogenesis of these fluctuations, a range of barriers across the gastrointestinal (GI) tract can alter levodopa pharmacokinetics, ultimately contributing to non‐optimal levodopa response and symptoms fluctuations. GI barriers to levodopa transport and absorption include dysphagia, delayed gastric emptying, constipation, Helicobacter pylori infection, small intestinal bacterial overgrowth and gut dysbiosis. In addition, a protein‐rich diet and concomitant medication intake can further alter levodopa pharmacokinetics. This can result in unpredictable or sub‐optimal levodopa response, ‘delayed on’ or ‘no on’ phenomena. In this narrative review, we provided an overview on the plethora of GI obstacles to levodopa transport and absorption in PD and their implications on levodopa pharmacokinetics and development of motor fluctuations. In addition, management strategies to address GI dysfunction in PD are highlighted, including use of non‐oral therapies to bypass the GI tract.
- 7 March 2023
- Published by Wiley in European Journal of Neurology
- Vol. 30 (5) , 1465-1480
Top Cited PapersOpen AccessGastrointestinal barriers to levodopa transport and absorption in Parkinson's disease
Levodopa is the gold standard for the symptomatic treatment of Parkinson's disease (PD). There are well documented motor and non‐motor fluctuations, however, that occur almost inevitably once levodopa is started after a variable period in people with PD. Whilst brain neurodegenerative processes play a part in the pathogenesis of these fluctuations, a range of barriers across the gastrointestinal (GI) tract can alter levodopa pharmacokinetics, ultimately contributing to non‐optimal levodopa response and symptoms fluctuations. GI barriers to levodopa transport and absorption include dysphagia, delayed gastric emptying, constipation, Helicobacter pylori infection, small intestinal bacterial overgrowth and gut dysbiosis. In addition, a protein‐rich diet and concomitant medication intake can further alter levodopa pharmacokinetics. This can result in unpredictable or sub‐optimal levodopa response, ‘delayed on’ or ‘no on’ phenomena. In this narrative review, we provided an overview on the plethora of GI obstacles to levodopa transport and absorption in PD and their implications on levodopa pharmacokinetics and development of motor fluctuations. In addition, management strategies to address GI dysfunction in PD are highlighted, including use of non‐oral therapies to bypass the GI tract.
- Open Access
- 7 January 2023
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 130 (6) , 783-791
The use of wearables for the diagnosis and treatment of Parkinson’s disease
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, with increasing numbers of affected patients. Many patients lack adequate care due to insufficient specialist neurologists/geriatricians, and older patients experience difficulties traveling far distances to reach their treating physicians. A new option for these obstacles would be telemedicine and wearables. During the last decade, the development of wearable sensors has allowed for the continuous monitoring of bradykinesia and dyskinesia. Meanwhile, other systems can also detect tremors, freezing of gait, and gait problems. The most recently developed systems cover both sides of the body and include smartphone apps where the patients have to register their medication intake and well-being. In turn, the physicians receive advice on changing the patient’s medication and recommendations for additional supportive therapies such as physiotherapy. The use of smartphone apps may also be adapted to detect PD symptoms such as bradykinesia, tremor, voice abnormalities, or changes in facial expression. Such tools can be used for the general population to detect PD early or for known PD patients to detect deterioration. It is noteworthy that most PD patients can use these digital tools. In modern times, wearable sensors and telemedicine open a new window of opportunity for patients with PD that are easy to use and accessible to most of the population.
- 7 January 2023
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 130 (6) , 783-791
Open AccessThe use of wearables for the diagnosis and treatment of Parkinson’s disease
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, with increasing numbers of affected patients. Many patients lack adequate care due to insufficient specialist neurologists/geriatricians, and older patients experience difficulties traveling far distances to reach their treating physicians. A new option for these obstacles would be telemedicine and wearables. During the last decade, the development of wearable sensors has allowed for the continuous monitoring of bradykinesia and dyskinesia. Meanwhile, other systems can also detect tremors, freezing of gait, and gait problems. The most recently developed systems cover both sides of the body and include smartphone apps where the patients have to register their medication intake and well-being. In turn, the physicians receive advice on changing the patient’s medication and recommendations for additional supportive therapies such as physiotherapy. The use of smartphone apps may also be adapted to detect PD symptoms such as bradykinesia, tremor, voice abnormalities, or changes in facial expression. Such tools can be used for the general population to detect PD early or for known PD patients to detect deterioration. It is noteworthy that most PD patients can use these digital tools. In modern times, wearable sensors and telemedicine open a new window of opportunity for patients with PD that are easy to use and accessible to most of the population.
- Open Access
- 23 December 2020
- Published by Wiley in European Journal of Neurology
- Vol. 28 (10) , 3437-3442
Neurology training and research in the COVID‐19 pandemic: a survey of the Resident and Research Fellow Section of the European Academy of Neurology
Background and purpose: The COVID‐19 (SARS‐CoV‐2) outbreak has disrupted residency programmes due to university and hospitals’ priorities to face this emergency at all cost. Most research projects and clinical trials were temporarily stopped or postponed. The Resident and Research Fellow Section (RRFS) of the European Academy of Neurology (EAN) has decided to assess the impact of the COVID‐19 pandemic on neurology training.Methods: All EAN RRFS members were invited to fill out an online questionnaire of 40 items concerning their clinical involvement during the COVID‐19 emergency, and the impact of the pandemic on their training (Appendix S1).Results: Of the 227 RRFS members who completed the questionnaire, 222 were from Europe, and of those 111 were from Portugal, Italy or France. Responders highlighted that severe restrictions have been imposed to face this pandemic, including reduction of inpatient beds, prohibition of in‐person visits and limitation to hospital access for patients’ relatives. This was accompanied by an increase in email correspondence and phone calls with 50% of countries allowing telemedicine to reach outpatients. Seventy‐nine per cent of the respondents felt that the pandemic will probably have a serious impact on their training and career.Conclusion: The pandemic led to a disruption of neurology activities, including medical training and research. The long‐run impact of these changes remains unknown, but it will probably change the way neurology practice and training will be organized for future generations.
- 23 December 2020
- Published by Wiley in European Journal of Neurology
- Vol. 28 (10) , 3437-3442
Open AccessNeurology training and research in the COVID‐19 pandemic: a survey of the Resident and Research Fellow Section of the European Academy of Neurology
Background and purpose: The COVID‐19 (SARS‐CoV‐2) outbreak has disrupted residency programmes due to university and hospitals’ priorities to face this emergency at all cost. Most research projects and clinical trials were temporarily stopped or postponed. The Resident and Research Fellow Section (RRFS) of the European Academy of Neurology (EAN) has decided to assess the impact of the COVID‐19 pandemic on neurology training.Methods: All EAN RRFS members were invited to fill out an online questionnaire of 40 items concerning their clinical involvement during the COVID‐19 emergency, and the impact of the pandemic on their training (Appendix S1).Results: Of the 227 RRFS members who completed the questionnaire, 222 were from Europe, and of those 111 were from Portugal, Italy or France. Responders highlighted that severe restrictions have been imposed to face this pandemic, including reduction of inpatient beds, prohibition of in‐person visits and limitation to hospital access for patients’ relatives. This was accompanied by an increase in email correspondence and phone calls with 50% of countries allowing telemedicine to reach outpatients. Seventy‐nine per cent of the respondents felt that the pandemic will probably have a serious impact on their training and career.Conclusion: The pandemic led to a disruption of neurology activities, including medical training and research. The long‐run impact of these changes remains unknown, but it will probably change the way neurology practice and training will be organized for future generations.
- Open Access
- 4 November 2020
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 128 (3) , 305-314
Emotional well-being and pain could be a greater determinant of quality of life compared to motor severity in cervical dystonia
Non-motor symptoms (NMS) occur in patients with cervical dystonia (CD) but with variable frequencies and impact on health-related quality of life (HRQoL). To define non-motor and motor profiles and their respective impact on HRQoL in CD patients using the newly validated Dystonia Non-Motor Symptoms Questionnaire (DNMSQuest). In an observational prospective multicentre case–control study, we enrolled 61 patients with CD and 61 age- and sex-matched healthy controls (HC) comparing demographic data, motor and non-motor symptoms and HRQoL measurements. 95% CD patients reported at least one NMS. Mean total NMS score was significantly higher in CD patients (5.62 ± 3.33) than in HC (1.74 ± 1.52; p < 0.001). Pain, insomnia and stigma were the most prevalent NMS and HRQoL was significantly impaired in CD patients compared to HC. There was strong correlation of NMS burden with HRQoL (CDQ-24: r = 0.72, EQ-5D: r = − 0.59; p < 0.001) in CD patients. Regression analysis between HRQoL and NMS suggested that emotional well-being (standardized beta = − 0.352) and pain (standardized beta = − 0.291) had a major impact on HRQoL while, in contrast motor severity had no significant impact in this model. Most NMS with the exception of pain, stigma and ADL did not correlate with motor severity. NMS are highly prevalent in CD patients and occur independent of age, sex, disease duration, duration of botulinum neurotoxin therapy and socio-economic status. Specific NMS such as emotional well-being and pain have a major impact on HRQoL and are more relevant than motor severity.
- 4 November 2020
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 128 (3) , 305-314
Open AccessEmotional well-being and pain could be a greater determinant of quality of life compared to motor severity in cervical dystonia
Non-motor symptoms (NMS) occur in patients with cervical dystonia (CD) but with variable frequencies and impact on health-related quality of life (HRQoL). To define non-motor and motor profiles and their respective impact on HRQoL in CD patients using the newly validated Dystonia Non-Motor Symptoms Questionnaire (DNMSQuest). In an observational prospective multicentre case–control study, we enrolled 61 patients with CD and 61 age- and sex-matched healthy controls (HC) comparing demographic data, motor and non-motor symptoms and HRQoL measurements. 95% CD patients reported at least one NMS. Mean total NMS score was significantly higher in CD patients (5.62 ± 3.33) than in HC (1.74 ± 1.52; p < 0.001). Pain, insomnia and stigma were the most prevalent NMS and HRQoL was significantly impaired in CD patients compared to HC. There was strong correlation of NMS burden with HRQoL (CDQ-24: r = 0.72, EQ-5D: r = − 0.59; p < 0.001) in CD patients. Regression analysis between HRQoL and NMS suggested that emotional well-being (standardized beta = − 0.352) and pain (standardized beta = − 0.291) had a major impact on HRQoL while, in contrast motor severity had no significant impact in this model. Most NMS with the exception of pain, stigma and ADL did not correlate with motor severity. NMS are highly prevalent in CD patients and occur independent of age, sex, disease duration, duration of botulinum neurotoxin therapy and socio-economic status. Specific NMS such as emotional well-being and pain have a major impact on HRQoL and are more relevant than motor severity.
- Open Access
Lower Energy Intake among Advanced vs. Early Parkinson’s Disease Patients and Healthy Controls in a Clinical Lunch Setting: A Cross-Sectional Study
Unintentional weight loss has been observed among Parkinson’s disease (PD) patients. Changes in energy intake (EI) and eating behavior, potentially caused by fine motor dysfunction and eating-related symptoms, might contribute to this. The primary aim of this study was to investigate differences in objectively measured EI between groups of healthy controls (HC), early (ESPD) and advanced stage PD patients (ASPD) during a standardized lunch in a clinical setting. The secondary aim was to identify clinical features and eating behavior abnormalities that explain EI differences. All participants (n = 23 HC, n = 20 ESPD, and n = 21 ASPD) went through clinical evaluations and were eating a standardized meal (200 g sausages, 400 g potato salad, 200 g apple purée and 500 mL water) in front of two video cameras. Participants ate freely, and the food was weighed pre- and post-meal to calculate EI (kcal). Multiple linear regression was used to explain group differences in EI. ASPD had a significantly lower EI vs. HC (−162 kcal, p < 0.05) and vs. ESPD (−203 kcal, p < 0.01) when controlling for sex. The number of spoonfuls, eating problems, dysphagia and upper extremity tremor could explain most (86%) of the lower EI vs. HC, while the first three could explain ~50% vs. ESPD. Food component intake analysis revealed significantly lower potato salad and sausage intakes among ASPD vs. both HC and ESPD, while water intake was lower vs. HC. EI is an important clinical target for PD patients with an increased risk of weight loss. Our results suggest that interventions targeting upper extremity tremor, spoonfuls, dysphagia and eating problems might be clinically useful in the prevention of unintentional weight loss in PD. Since EI was lower in ASPD, EI might be a useful marker of disease progression in PD.
Open AccessLower Energy Intake among Advanced vs. Early Parkinson’s Disease Patients and Healthy Controls in a Clinical Lunch Setting: A Cross-Sectional Study
Unintentional weight loss has been observed among Parkinson’s disease (PD) patients. Changes in energy intake (EI) and eating behavior, potentially caused by fine motor dysfunction and eating-related symptoms, might contribute to this. The primary aim of this study was to investigate differences in objectively measured EI between groups of healthy controls (HC), early (ESPD) and advanced stage PD patients (ASPD) during a standardized lunch in a clinical setting. The secondary aim was to identify clinical features and eating behavior abnormalities that explain EI differences. All participants (n = 23 HC, n = 20 ESPD, and n = 21 ASPD) went through clinical evaluations and were eating a standardized meal (200 g sausages, 400 g potato salad, 200 g apple purée and 500 mL water) in front of two video cameras. Participants ate freely, and the food was weighed pre- and post-meal to calculate EI (kcal). Multiple linear regression was used to explain group differences in EI. ASPD had a significantly lower EI vs. HC (−162 kcal, p < 0.05) and vs. ESPD (−203 kcal, p < 0.01) when controlling for sex. The number of spoonfuls, eating problems, dysphagia and upper extremity tremor could explain most (86%) of the lower EI vs. HC, while the first three could explain ~50% vs. ESPD. Food component intake analysis revealed significantly lower potato salad and sausage intakes among ASPD vs. both HC and ESPD, while water intake was lower vs. HC. EI is an important clinical target for PD patients with an increased risk of weight loss. Our results suggest that interventions targeting upper extremity tremor, spoonfuls, dysphagia and eating problems might be clinically useful in the prevention of unintentional weight loss in PD. Since EI was lower in ASPD, EI might be a useful marker of disease progression in PD.
- Open Access
- 6 March 2020
- Published by Springer Nature in Der Nervenarzt
- Vol. 91 (4) , 337-342
Dystonia Non-Motor Symptoms Questionnaire (DNMSQuest) zur Erhebung nichtmotorischer Symptome bei Dystonie
Zusammenfassung Hintergrund Nichtmotorische Symptome (NMS) bei Patienten mit Dystonie haben einen relevanten Einfluss auf die Lebensqualität. Ein rein auf NMS bei Dystonie bezogenes Messinstrument existiert nicht. Ziel Die validierte deutsche Version des Dystonia Non-Motor Symptoms Questionnaire (DNMSQuest) zur Erhebung von NMS bei kraniozervikaler Dystonie wird hier vorgestellt. Methoden Der DNMSQuest in deutscher Sprache wurde nach international anerkannten Standards zum Vorgehen der interkulturellen Adaptation selbst auszufüllender Patientenfragebögen erstellt. So erfolgte die Übersetzung des englischen Originalfragebogens ins Deutsche sowie die Rückübersetzung unabhängig voneinander durch insgesamt vier bilinguale Neurologen mit Schwerpunkt Bewegungsstörungen. Von einem weiteren Neurologen wurde jeweils eine von den Übersetzern akzeptierte Konsensusfassung erstellt. Der englische Originalfragebogen wurde mit der rückübersetzten englischen Version von einem Neurologen mit maßgeblicher Beteiligung an der Entwicklung des Originalfragebogens auf sprachliche und inhaltliche Abweichungen kontrolliert. Die finale deutsche Version wurde bei 130 Patienten mit zervikaler Dystonie sowie 48 gesunden Kontrollen bei der internationalen, multizentrischen Validierungsstudie angewendet. Ergebnisse Es entstand eine interkulturell adaptierte, in deutscher und englischer Sprache validierte Fassung des DNMSQuest. Diskussion Der DNMSQuest kann die aktuell bestehende Lücke eines validierten, krankheitsspezifischen, durch die Patienten selbst auszufüllenden, kurzen, umfassenden Fragebogen zur Erhebung von NMS bei zervikaler Dystonie schließen. Er kann einfach in den klinischen Alltag integriert werden und empfiehlt sich für die klinische Praxis sowie zur Anwendung in klinischen Studien.
- 6 March 2020
- Published by Springer Nature in Der Nervenarzt
- Vol. 91 (4) , 337-342
Open AccessDystonia Non-Motor Symptoms Questionnaire (DNMSQuest) zur Erhebung nichtmotorischer Symptome bei Dystonie
Zusammenfassung Hintergrund Nichtmotorische Symptome (NMS) bei Patienten mit Dystonie haben einen relevanten Einfluss auf die Lebensqualität. Ein rein auf NMS bei Dystonie bezogenes Messinstrument existiert nicht. Ziel Die validierte deutsche Version des Dystonia Non-Motor Symptoms Questionnaire (DNMSQuest) zur Erhebung von NMS bei kraniozervikaler Dystonie wird hier vorgestellt. Methoden Der DNMSQuest in deutscher Sprache wurde nach international anerkannten Standards zum Vorgehen der interkulturellen Adaptation selbst auszufüllender Patientenfragebögen erstellt. So erfolgte die Übersetzung des englischen Originalfragebogens ins Deutsche sowie die Rückübersetzung unabhängig voneinander durch insgesamt vier bilinguale Neurologen mit Schwerpunkt Bewegungsstörungen. Von einem weiteren Neurologen wurde jeweils eine von den Übersetzern akzeptierte Konsensusfassung erstellt. Der englische Originalfragebogen wurde mit der rückübersetzten englischen Version von einem Neurologen mit maßgeblicher Beteiligung an der Entwicklung des Originalfragebogens auf sprachliche und inhaltliche Abweichungen kontrolliert. Die finale deutsche Version wurde bei 130 Patienten mit zervikaler Dystonie sowie 48 gesunden Kontrollen bei der internationalen, multizentrischen Validierungsstudie angewendet. Ergebnisse Es entstand eine interkulturell adaptierte, in deutscher und englischer Sprache validierte Fassung des DNMSQuest. Diskussion Der DNMSQuest kann die aktuell bestehende Lücke eines validierten, krankheitsspezifischen, durch die Patienten selbst auszufüllenden, kurzen, umfassenden Fragebogen zur Erhebung von NMS bei zervikaler Dystonie schließen. Er kann einfach in den klinischen Alltag integriert werden und empfiehlt sich für die klinische Praxis sowie zur Anwendung in klinischen Studien.
- Open Access
- 24 December 2019
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Biomedical and Health Informatics
- Vol. 24 (9) , 2559-2569
Detecting Parkinsonian Tremor From IMU Data Collected in-the-Wild Using Deep Multiple-Instance Learning
Parkinson's Disease (PD) is a slowly evolving neuro-logical disease that affects about 1% of the population above 60 years old, causing symptoms that are subtle at first, but whose intensity increases as the disease progresses. Automated detection of these symptoms could offer clues as to the early onset of the disease, thus improving the expected clinical outcomes of the patients via appropriately targeted interventions. This potential has led many researchers to develop methods that use widely available sensors to measure and quantify the presence of PD symptoms such as tremor, rigidity and braykinesia. However, most of these approaches operate under controlled settings, such as in lab or at home, thus limiting their applicability under free-living conditions. In this work, we present a method for automatically identifying tremorous episodes related to PD, based on IMU signals captured via a smartphone device. We propose a Multiple-Instance Learning approach, wherein a subject is represented as an unordered bag of accelerometer signal segments and a single, expert-provided, tremor annotation. Our method combines deep feature learning with a learnable pooling stage that is able to identify key instances within the subject bag, while still being trainable end-to-end. We validate our algo- rithm on a newly introduced dataset of 45 subjects, containing accelerometer signals collected entirely in-the-wild. The good classification performance obtained in the conducted experiments suggests that the proposed method can efficiently navigate the noisy environment of in-the-wild recordings.
- 24 December 2019
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Biomedical and Health Informatics
- Vol. 24 (9) , 2559-2569
Open AccessDetecting Parkinsonian Tremor From IMU Data Collected in-the-Wild Using Deep Multiple-Instance Learning
Parkinson's Disease (PD) is a slowly evolving neuro-logical disease that affects about 1% of the population above 60 years old, causing symptoms that are subtle at first, but whose intensity increases as the disease progresses. Automated detection of these symptoms could offer clues as to the early onset of the disease, thus improving the expected clinical outcomes of the patients via appropriately targeted interventions. This potential has led many researchers to develop methods that use widely available sensors to measure and quantify the presence of PD symptoms such as tremor, rigidity and braykinesia. However, most of these approaches operate under controlled settings, such as in lab or at home, thus limiting their applicability under free-living conditions. In this work, we present a method for automatically identifying tremorous episodes related to PD, based on IMU signals captured via a smartphone device. We propose a Multiple-Instance Learning approach, wherein a subject is represented as an unordered bag of accelerometer signal segments and a single, expert-provided, tremor annotation. Our method combines deep feature learning with a learnable pooling stage that is able to identify key instances within the subject bag, while still being trainable end-to-end. We validate our algo- rithm on a newly introduced dataset of 45 subjects, containing accelerometer signals collected entirely in-the-wild. The good classification performance obtained in the conducted experiments suggests that the proposed method can efficiently navigate the noisy environment of in-the-wild recordings.
- Open Access
- 27 September 2019
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 6 (10) , 2054-2065
Validation of a self‐completed Dystonia Non‐Motor Symptoms Questionnaire
Objective: To develop and validate a novel 14‐item self‐completed questionnaire (in English and German) enquiring about the presence of non‐motor symptoms (NMS) during the past month in patients with craniocervical dystonia in an international multicenter study.Methods: The Dystonia Non‐Motor Symptoms Questionnaire (DNMSQuest) covers seven domains including sleep, autonomic symptoms, fatigue, emotional well‐being, stigma, activities of daily living, sensory symptoms. The feasibility and clinimetric attributes were analyzed.Results: Data from 194 patients with CD (65.6% female, mean age 58.96 ± 12.17 years, duration of disease 11.95 ± 9.40 years) and 102 age‐ and sex‐matched healthy controls (66.7% female, mean age 55.67 ± 17.62 years) were collected from centres in Germany and the UK. The median total NMS score in CD patients was 5 (interquartile range 3–7), significantly higher than in healthy controls with 1 (interquartile range 0.75–2.25) (P < 0.001, Mann–Whitney U‐test). Evidence for intercorrelation and convergent validity is shown by moderate to high correlations of total DNMSQuest score with motor symptom severity (TWSTRS: rs = 0.61), clinical global impression (rs = 0.40), and health‐related quality of life measures: CDQ‐24 (rs = 0.74), EQ‐5D index (rs = −0.59), and scale (rs = −0.49) (all P < 0.001). Data quality and acceptability was very satisfactory.Interpretation: The DNMSQuest, a patient self‐completed questionnaire for NMS assessment in CD patients, appears robust, reproducible, and valid in clinical practice showing a tangible impact of NMS on quality of life in CD. As there is no specific, comprehensive, validated tool to assess the burden of NMS in dystonia, the DNMSQuest can bridge this gap and could easily be integrated into clinical practice.
- 27 September 2019
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 6 (10) , 2054-2065
Open AccessValidation of a self‐completed Dystonia Non‐Motor Symptoms Questionnaire
Objective: To develop and validate a novel 14‐item self‐completed questionnaire (in English and German) enquiring about the presence of non‐motor symptoms (NMS) during the past month in patients with craniocervical dystonia in an international multicenter study.Methods: The Dystonia Non‐Motor Symptoms Questionnaire (DNMSQuest) covers seven domains including sleep, autonomic symptoms, fatigue, emotional well‐being, stigma, activities of daily living, sensory symptoms. The feasibility and clinimetric attributes were analyzed.Results: Data from 194 patients with CD (65.6% female, mean age 58.96 ± 12.17 years, duration of disease 11.95 ± 9.40 years) and 102 age‐ and sex‐matched healthy controls (66.7% female, mean age 55.67 ± 17.62 years) were collected from centres in Germany and the UK. The median total NMS score in CD patients was 5 (interquartile range 3–7), significantly higher than in healthy controls with 1 (interquartile range 0.75–2.25) (P < 0.001, Mann–Whitney U‐test). Evidence for intercorrelation and convergent validity is shown by moderate to high correlations of total DNMSQuest score with motor symptom severity (TWSTRS: rs = 0.61), clinical global impression (rs = 0.40), and health‐related quality of life measures: CDQ‐24 (rs = 0.74), EQ‐5D index (rs = −0.59), and scale (rs = −0.49) (all P < 0.001). Data quality and acceptability was very satisfactory.Interpretation: The DNMSQuest, a patient self‐completed questionnaire for NMS assessment in CD patients, appears robust, reproducible, and valid in clinical practice showing a tangible impact of NMS on quality of life in CD. As there is no specific, comprehensive, validated tool to assess the burden of NMS in dystonia, the DNMSQuest can bridge this gap and could easily be integrated into clinical practice.